Form D · Biotechnology

Adgero Biopharmaceuticals Holdings, Inc.

Princeton, NJ · CIK 0001657598

Offering snapshot reported Sep 9, 2016 · SEC filing

Reported sold: $459K
Investors reported: 21
Minimum accepted: $0
First sale: Aug 31, 2016

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 9, 2016	Initial	$459,000	No comparison	21	SEC filing
Apr 19, 2016	Initial	$3,024,730	No comparison	39	SEC filing
Nov 24, 2015	Initial	$39,750	No comparison	9	SEC filing

Offering details

Securities: Equity, Option to acquire, Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $260K (estimated)
Finders' fees: $0
Form D file number: 021-270406

Units consisting of common stock and warrants

Placement Agent is entitled to receive 10% cash and 3% expense fees. Assumes maximum offering sold and commissions paid pursuant to over-allotment. Does not include up to 80,000 warrants issuable to Placement Agent.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Aegis Capital Corp.	15007

Source: Form D, filed Sep 9, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Allen Bloom	Director
John Brancaccio	Executive
David P. Hochman	Director
Tim Mc Inerney	Director
Roman Perez Soler	Director
Frank Pilkiewicz	Director, Executive
Steve Rychnovsky	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

301 N. Harrison St. Suite 9 F #459
Princeton, NJ, 08540